NCT00001538View on ClinicalTrials.gov

Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 1996

Study Completion Date

April 30, 2001

Conditions
Acquired Immunodeficiency SyndromeHIV Infection
Interventions
BIOLOGICAL

APL 400-003

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001538 - Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers | Biotech Hunter | Biotech Hunter